Table 1.
Characteristics of the study population (A) and clinical data of Juvenile Idiopathic Arthritis patients (B)
| (A) Study population | JIA | HC |
| Number of samples | 14 | 10 |
|
Numbers of male (%)/ female (%) |
6 (42.9%)/ 8 (57.1%) |
2 (20%)/ 8 (80%) |
| Age at time of inclusion (years) | 16.1 ± 5.0 (16; 8–27) | 23.4 ± 1.69 (23.5; 19–25) |
| Age at time of diagnosis (years) | 5 ± 4.1 (3.5; 1–15) | - |
| Disease duration (years) | 11.1 ± 6.0 (12.5; 1–24) | - |
| (B) Clinical Data in JIA | ||
| Medication | 13/92.9% | |
| Nonsteroidal anti-inflammatory drug (in therapeutic dosages) | 7/50% | |
| Methotrexate (at < 15 mg/m2/week) | 7/50% | |
| Glucocorticoids (at < 0.1 mg/kg/d) | 3/21.4% | |
| Biologicals (in therapeutic dosages) | 10/71.4% | |
| Tocilizumab 1/7.1% | ||
| Adalimumab 4/28.6% | ||
| Abatacept 2/14.3% | ||
| Etanercept 3/21.4% | ||
| Mycophenolate Mofetil | 2/14.3% | |
| Antinuclear antibodies positive | 11/78.6% | |
| Rheumatoid factor positive | 0/0% | |
| C-reactive protein (mg/dl) | 0.2 ± 0.3 (0.0; 0–0.9) | |
| Erythrocyte sedimentation rate (mm/h) | 11.7 ± 10.7 (6.5; 2–35) | |
| Leukocytes (× 103 per μl) | 7.0 ± 2.3 (6.7; 2.4–11.5) | |
| Lymphocytes (G/l) | 2.6 ± 0.8 (2.6; 1.3–4.3) | |
| Lymphocytes (%) | 39.9 ± 10.6 (39.5; 13.8–64) | |
| Thrombocytes (× 103 per μl) | 231.3 ± 54.6 (232; 138–327) | |
| Immunoglobulin G (mg/dl) | 912.9 ± 353.1 (992; 133–1309) | |
| Active joints |
4/28.5% ACR active joints if positive: 1; 3; 3; 4 |
|
Characteristics of the study population are shown in (A). Values are given in absolute numbers (percentages) or as mean ± SD (median; minimum to maximum). HC healthy controls, JIA Juvenile Idiopathic Arthritis
Clinical data of Juvenile Idiopathic Arthritis (JIA) patients are gathered in (B). Number of patients = 14. Values are given in absolute numbers/percentages or as mean ± SD (median; minimum—maximum). ACR American College of Rheumatology